Can you take Brentuximab with Myrac?

The brentuximab vedotin in brentuximab has a moderate potential interaction with Diabetes Mellitus.

Serious events of hyperglycemia (e.g., new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, ketoacidosis [including fatalities]) have been reported in brentuximab vedotin-treated patients. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Serum glucose should be monitored and if hyperglycemia develops, antihyperglycemic agents should be administered as clinically indicated.

The minocycline in Myrac has a moderate potential interaction with Esophageal Obstruction.

The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime. Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia. If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Gastrointestinal Obstruction.

Fatal and serious events of acute pancreatitis have been reported with brentuximab vedotin. Other fatal and serious gastrointestinal (GI) complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. If new or worsening GI symptoms (including severe abdominal pain) develop, it is recommended to perform a prompt diagnostic evaluation and treat appropriately.

The brentuximab vedotin in brentuximab has a major potential interaction with Infection.

Serious infections and opportunistic infections (e.g., pneumonia, bacteremia, sepsis/septic shock [including fatalities]) have been reported in patients treated with brentuximab vedotin. Patients should be monitored closely for the emergence of any infection during treatment with this agent. John Cunningham virus (JC virus) infection resulting in progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent. A diagnosis of PML should be considered in any patient presenting with new-onset signs/symptoms of CNS abnormalities. Therapy should be held for any suspected case of PML and discontinued if a diagnosis of PML is confirmed.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Liver Disease.

The use of brentuximab vedotin should be avoided in patients with moderate or severe liver dysfunction (Child-Pugh B or C). The frequency of grade 3 or higher adverse reactions and deaths was greater in patients with moderate and severe liver dysfunction compared to those with normal liver function. Fatal and serious cases of hepatotoxicity have occurred in patients receiving this agent. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Liver enzymes and bilirubin should be monitored. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of brentuximab vedotin.

The minocycline in Myrac has a moderate potential interaction with Liver Disease.

The use of tetracyclines has rarely been associated with hepatotoxicity. Histologic fatty changes of the liver, elevated liver enzymes, and jaundice have been reported, primarily in patients treated with large doses of intravenous tetracycline hydrochloride (no longer available in the U.S.) but also in patients receiving high oral doses of these drugs. Therapy with tetracyclines should be administered cautiously in patients with preexisting liver disease or biliary obstruction. Reduced dosages may be appropriate, particularly with minocycline and doxycycline, since the former is metabolized by the liver and the latter undergoes enterohepatic recycling. Liver function tests are recommended prior to and during therapy, and the concomitant use of other potentially hepatotoxic drugs should be avoided.

The minocycline in Myrac has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Peripheral Neuropathy.

Peripheral neuropathy, predominantly sensory neuropathy, has occurred in patients treated with brentuximab vedotin. Patients should be monitored for symptoms of neuropathy, and those experiencing new or worsening peripheral neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Pulmonary Impairment.

Fatal and serious events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported with the use of brentuximab vedotin. Care should be taken when using this agent in patients at risk of pulmonary events. Patients should be monitored for signs/symptoms of pulmonary toxicity (including cough and dyspnea). If new or worsening pulmonary symptoms develop, brentuximab vedotin dosing should be held during evaluation and until symptomatic improvement.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Renal Dysfunction.

The use of brentuximab vedotin should be avoided in patients with severe renal dysfunction (CrCl less than 30 mL/min). The frequency of grade 3 or higher adverse reactions and deaths was greater in patients with severe renal dysfunction compared to those with normal renal function.

The minocycline in Myrac has a moderate potential interaction with Renal Dysfunction.

Tetracyclines (except doxycycline) are eliminated by the kidney to various extent. Patients with renal impairment may be at greater risk for tetracycline-associated hepatic and/or renal toxicity (increased BUN with consequent azotemia, hyperphosphatemia, and acidosis) due to decreased drug clearance. Therapy with tetracyclines should be administered cautiously at reduced dosages in patients with renal impairment. Clinical monitoring of renal and liver function is recommended, and serum tetracycline levels may be necessary during prolonged therapy.

The brentuximab vedotin in brentuximab has a major potential interaction with Tumor Lysis Syndrome.

Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and/or high circulating lymphocyte counts (greater than 25 x 10[9]/L) are at greater risk for developing TLS. Tumor lysis prophylaxis with anti-hyperuricemics and hydration prior to infusion may be recommended or should be considered. Electrolyte abnormalities should be corrected, and renal function and fluid balance should be monitored in patients who develop TLS. It is recommended to monitor for signs/symptoms of TLS, and temporary interruption or discontinuation of therapy might be required.

The brentuximab vedotin in brentuximab has a moderate potential interaction with Weight Loss.

Serious events of hyperglycemia (e.g., new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, ketoacidosis [including fatalities]) have been reported in brentuximab vedotin-treated patients. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Serum glucose should be monitored and if hyperglycemia develops, antihyperglycemic agents should be administered as clinically indicated.